| Year |
Citation |
Score |
| 2012 |
Taylor JL, White SR, Lauring B, Kull FJ. Crystal structure of the human spastin AAA domain. Journal of Structural Biology. 179: 133-7. PMID 22446388 DOI: 10.1016/J.Jsb.2012.03.002 |
0.442 |
|
| 2007 |
White SR, Lauring B. AAA+ ATPases: achieving diversity of function with conserved machinery. Traffic (Copenhagen, Denmark). 8: 1657-67. PMID 17897320 DOI: 10.1111/J.1600-0854.2007.00642.X |
0.412 |
|
| 2007 |
Nikonov AV, Hauri HP, Lauring B, Kreibich G. Climp-63-mediated binding of microtubules to the ER affects the lateral mobility of translocon complexes. Journal of Cell Science. 120: 2248-58. PMID 17567679 DOI: 10.1242/Jcs.008979 |
0.319 |
|
| 2007 |
White SR, Evans KJ, Lary J, Cole JL, Lauring B. Recognition of C-terminal amino acids in tubulin by pore loops in Spastin is important for microtubule severing. The Journal of Cell Biology. 176: 995-1005. PMID 17389232 DOI: 10.1083/Jcb.200610072 |
0.542 |
|
| 2006 |
Evans K, Keller C, Pavur K, Glasgow K, Conn B, Lauring B. Interaction of two hereditary spastic paraplegia gene products, spastin and atlastin, suggests a common pathway for axonal maintenance. Proceedings of the National Academy of Sciences of the United States of America. 103: 10666-71. PMID 16815977 DOI: 10.1073/Pnas.0510863103 |
0.548 |
|
| 2005 |
Black VH, Sanjay A, van Leyen K, Lauring B, Kreibich G. Cholesterol and steroid synthesizing smooth endoplasmic reticulum of adrenocortical cells contains high levels of proteins associated with the translocation channel. Endocrinology. 146: 4234-49. PMID 15947003 DOI: 10.1210/En.2005-0372 |
0.319 |
|
| 2005 |
Evans KJ, Gomes ER, Reisenweber SM, Gundersen GG, Lauring BP. Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing. The Journal of Cell Biology. 168: 599-606. PMID 15716377 DOI: 10.1083/Jcb.200409058 |
0.579 |
|
| 2002 |
Black VH, Sanjay A, van Leyen K, Möeller I, Lauring B, Kreibich G. Cholesterol and steroid synthesizing smooth endoplasmic reticulum of adrenocortical cells contains high levels of translocation apparatus proteins. Endocrine Research. 28: 425-30. PMID 12530645 DOI: 10.1081/Erc-120016818 |
0.316 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2005 |
Keller CE, Lauring BP. Possible regulation of microtubules through destabilization of tubulin. Trends in Cell Biology. 15: 571-3. PMID 16202601 DOI: 10.1016/j.tcb.2005.09.008 |
0.287 |
|
| 2003 |
Martinez J, Moeller I, Erdjument-Bromage H, Tempst P, Lauring B. Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. The Journal of Biological Chemistry. 278: 17379-87. PMID 12610000 DOI: 10.1074/jbc.M209020200 |
0.2 |
|
| 1998 |
Möller I, Beatrix B, Kreibich G, Sakai H, Lauring B, Wiedmann M. Unregulated exposure of the ribosomal M-site caused by NAC depletion results in delivery of non-secretory polypeptides to the Sec61 complex. Febs Letters. 441: 1-5. PMID 9877153 DOI: 10.1016/S0014-5793(98)01440-9 |
0.161 |
|
| 1998 |
Möller I, Jung M, Beatrix B, Levy R, Kreibich G, Zimmermann R, Wiedmann M, Lauring B. A general mechanism for regulation of access to the translocon: competition for a membrane attachment site on ribosomes. Proceedings of the National Academy of Sciences of the United States of America. 95: 13425-30. PMID 9811816 DOI: 10.1073/Pnas.95.23.13425 |
0.159 |
|
| 2014 |
Lauring B, Dishy V, De Kam PJ, Crumley T, Wenning L, Liu F, Sisk C, Wagner J, Lai E. Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects. American Journal of Therapeutics. PMID 24832384 DOI: 10.1097/MJT.0000000000000051 |
0.093 |
|
| 2012 |
Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Science Translational Medicine. 4: 148ra115. PMID 22914621 DOI: 10.1126/Scitranslmed.3003877 |
0.091 |
|
| 2017 |
Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, Jiang ZW, Golm G, Engel SS, Lauring B. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 29159457 DOI: 10.1007/s13300-017-0337-5 |
0.086 |
|
| 2012 |
Boatman PD, Lauring B, Schrader TO, Kasem M, Johnson BR, Skinner P, Jung JK, Xu J, Cherrier MC, Webb PJ, Semple G, Sage CR, Knudsen J, Chen R, Luo WL, et al. (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans. Journal of Medicinal Chemistry. 55: 3644-66. PMID 22435740 DOI: 10.1021/Jm2010964 |
0.077 |
|
| 2018 |
Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal. 206: 11-23. PMID 30290289 DOI: 10.1016/j.ahj.2018.08.016 |
0.066 |
|
| 2019 |
Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes, Obesity & Metabolism. PMID 30614616 DOI: 10.1111/dom.13631 |
0.059 |
|
| 2017 |
Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion. 1-19. PMID 28548024 DOI: 10.1080/03007995.2017.1335638 |
0.058 |
|
| 2014 |
Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AO, Lasseter KC, Preston RA, Smith WB, Lai E, Wagner JA. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. Journal of Clinical Pharmacology. 54: 1247-55. PMID 24782116 DOI: 10.1002/jcph.320 |
0.058 |
|
| 2014 |
Lauring B, Liu Y, Li XS, Larson P, Moreau A, Farmer HF, Johnson-Levonas AO, Wagner JA, Lai E. Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers. Journal of Clinical Pharmacology. 54: 765-75. PMID 24615657 DOI: 10.1002/jcph.278 |
0.056 |
|
| 2018 |
GALLO S, CHARBONNEL B, GOLDMAN A, SHI H, HUYCK S, DAREKAR A, LAURING B, TERRA S. Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial Diabetes. 67: 1129-P. DOI: 10.2337/db18-1129-P |
0.055 |
|
| 2002 |
Nasr SH, Lobritto SJ, Lauring BP, Arend LJ, D'Agati VD, Markowitz GS. A rare complication of monoclonal gammopathy. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 40: 867-71. PMID 12324928 DOI: 10.1053/ajkd.2002.35702 |
0.054 |
|
| 2017 |
Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes, Obesity & Metabolism. PMID 28921862 DOI: 10.1111/dom.13116 |
0.053 |
|
| 2019 |
Hollander P, Hill J, Johnson J, Jiang ZW, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B, Liu J. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Current Medical Research and Opinion. 1. PMID 30760125 DOI: 10.1080/03007995.2019.1583450 |
0.053 |
|
| 2017 |
Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin Plus Sitagliptin Versus Either Individual Agent Over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin: The VERTIS FACTORIAL Randomized Trial. Diabetes, Obesity & Metabolism. PMID 29266675 DOI: 10.1111/dom.13194 |
0.05 |
|
| 2018 |
Miller S, Krumins T, Zhou H, Huyck S, Johnson J, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 29313282 DOI: 10.1007/S13300-017-0358-0 |
0.048 |
|
| 2017 |
Hollander P, Liu J, Hill J, Johnson J, Jiang ZW, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 29282633 DOI: 10.1007/s13300-017-0354-4 |
0.047 |
|
| 2019 |
Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, Mu Y, Yan P, Pan S, Lauring B, Liu S, Huyck S, Qiu Y, Terra SG. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes, Obesity & Metabolism. PMID 30830724 DOI: 10.1111/dom.13681 |
0.047 |
|
| 2009 |
Lauring B, Rosko K, Luo WL, Wenning L, Kissling J, Roupe K, Paolini JF, Wagner J, Lai E. A comparison of the pharmacokinetics of two different formulations of extended-release niacin. Current Medical Research and Opinion. 25: 15-22. PMID 19210135 DOI: 10.1185/03007990802569034 |
0.046 |
|
| 2018 |
Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, Obesity & Metabolism. PMID 29419917 DOI: 10.1111/dom.13251 |
0.046 |
|
| 2009 |
Lauring B, Dishy V, Luo WL, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, Lai E. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. Journal of Clinical Pharmacology. 49: 1426-35. PMID 19833861 DOI: 10.1177/0091270009339593 |
0.045 |
|
| 2017 |
Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S. A Phase 3, Efficacy and Safety Study of Ertugliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone. Diabetes, Obesity & Metabolism. PMID 28116776 DOI: 10.1111/dom.12888 |
0.044 |
|
| 2017 |
Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes, Obesity & Metabolism. PMID 28857451 DOI: 10.1111/dom.13103 |
0.044 |
|
| 2018 |
LIU J, TARASENKO L, PONG A, HUYCK S, WU L, MANCUSO JP, TERRA S, LAURING B. Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM) Diabetes. 67: 1132-P. DOI: 10.2337/DB18-1132-P |
0.042 |
|
| 2018 |
PATEL SM, HICKMAN MA, FREDERICH R, LAURING B, TERRA S, JOHNSON SL, HUYCK S, MANCUSO JP. Assessment of Adverse Renal Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin Diabetes. 67: 1168-P. DOI: 10.2337/DB18-1168-P |
0.041 |
|
| 2018 |
PATEL SM, HICKMAN MA, FREDERICH R, LAURING B, TERRA S, JOHNSON SL, HUYCK S, MANCUSO JP. Evaluation of Osmotic Diuresis and Volume Depletion Events in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin Diabetes. 67: 1169-P. DOI: 10.2337/DB18-1169-P |
0.035 |
|
| 2018 |
CALLE RA, LIU J, HUYCK S, WU L, PONG A, MANCUSO JP, TERRA S, LAURING B. A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin Diabetes. 67: 1140-P. DOI: 10.2337/DB18-1140-P |
0.029 |
|
| 2013 |
Engel SS, Golm GT, Lauring B. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604. Diabetes. 62: e18. PMID 24065799 DOI: 10.2337/db13-0525 |
0.022 |
|
| 2018 |
Liu J, Pong A, Gallo S, Darekar A, Terra S, Lauring B. EFFECTS OF ERTUGLIFLOZIN ON BLOOD PRESSURE AND PULSE RATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Journal of the American College of Cardiology. 71: A1810. DOI: 10.1016/s0735-1097(18)32351-9 |
0.022 |
|
| 2018 |
HICKMAN MA, FREDERICH R, PATEL SM, GALLO S, LAURING B, TERRA S, JOHNSON SL, MASIUKIEWICZ U, HUYCK S, MANCUSO JP. Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin Diabetes. 67: 1145-P. DOI: 10.2337/DB18-1145-P |
0.016 |
|
| Hide low-probability matches. |